Arcutis Biotherapeutics (ARQT) said Thursday that its Zoryve cream 0.15% received a "strong recommendation" from the American Academy of Dermatology for the management of adult atopic dermatitis.
The recommendation, in an AAD focused update paper, mentions Zoryve's ability to deliver clinically meaningful improvements in pruritus and disease severity as a non-steroid option for daily disease management, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.